Crystal's MCW Coder Hub🧬ICD-10 CM H35.721 — Serous Detachment of Retinal Pigment Epithelium, Right Eye
Quick Reference
Code: H35.721 | Billable: Yes | Chapter: 7 — Eye and Adnexa | HCC Cat: 124 | Coefficient: 0.191 | Laterality: Right eye required
Description
ICD-10 CM H35.721 identifies serous detachment of the retinal pigment epithelium (RPE) of the right eye — a condition in which serous (protein-rich, non-hemorrhagic) fluid accumulates in the potential space between the RPE and Bruch’s membrane, causing the RPE to dome or lift away from its normal anatomic position. This is distinctly different from a full retinal detachment (H33.-), which involves separation of the neurosensory retina from the RPE, and from hemorrhagic RPE detachment (H35.731), in which blood — not serous fluid — underlies the RPE.
Also known as: serous pigment epithelial detachment (serous PED), serous RPE detachment, drusenoid PED (when fluid accumulates beneath a large drusen or confluent drusen), and fibrovascular PED (when associated with occult choroidal neovascularization — though strictly speaking, fibrovascular PED involves neovascular tissue, not pure serous fluid).
Serous PED most commonly presents in the context of exudative (wet) age-related macular degeneration with choroidal neovascularization (CNV), and may also occur in central serous chorioretinopathy (though CSCR-related RPE detachments code more accurately to H35.711 when that is the primary diagnosis). When PED is secondary to wet AMD, always code the AMD separately — the two conditions are independently reportable and both carry HCC weight.
Code Structure & Hierarchy
Code Tree
- Chapter: 7 — Diseases of the Eye and Adnexa (H00-H59)
- Block: H30-H36 — Disorders of Choroid and Retina
- H35 — Other retinal disorders
- H35.7 — Separation of retinal layers ← this branch
- H35.70 — Unspecified separation of retinal layers
- H35.71 — Central serous chorioretinopathy
- H35.72 — Serous detachment of RPE ← this subcategory
- H35.73 — Hemorrhagic detachment of RPE
Serous vs. Hemorrhagic PED — Critical Distinction
Feature Serous PED (H35.721) Hemorrhagic PED (H35.731) Fluid type Serous / protein-rich Blood / hemorrhagic OCT appearance Dome-shaped, optically clear sub-RPE space High internal reflectivity under RPE FA appearance Pooling, smooth margins Blocked fluorescence Association AMD, CSCR, occult CNV Wet AMD with CNV, trauma, anticoagulation Prognosis Variable; may convert to hemorrhagic Worse; fibrosis/scarring risk higher Code H35.721 H35.731 OCT and fluorescein angiography (FA) or OCT-A are the definitive diagnostic tools for distinguishing serous from hemorrhagic PED. Provider documentation must reflect the type — do not infer from imaging reports without provider confirmation in the assessment.
Instructional Notes
Excludes2 — Not Included Here, May Co-exist
The following may be coded in addition to H35.721 when separately documented:
- Central serous chorioretinopathy, right eye (H35.711) — when CSCR is the primary diagnosis and RPE detachment is a secondary finding; however, evaluate carefully — if the PED is solely a feature of CSCR, coding both may overstate the clinical picture; provider guidance preferred
- Hemorrhagic detachment of RPE, right eye (H35.731) — if both serous and hemorrhagic components are separately documented in the same eye (e.g., mixed PED on OCT); query provider for documentation of both components
- Exudative AMD (H35.3211) — most common co-diagnosis; code separately as the underlying etiology when documented; both carry HCC 124 weight independently
- Macular hole or cyst (H35.341) — separately reportable when confirmed as a distinct finding
Excludes1 — Mutually Exclusive
Cannot be coded together with H35.721:
- Retinal detachment with retinal break (H33.0-) — full-thickness neurosensory detachment is a distinct and more severe condition; when rhegmatogenous detachment is present, it supersedes RPE detachment coding for that eye unless both are separately documented and clinically distinct
Use Additional Code
Always code the underlying or associated condition when PED is secondary:
- Exudative AMD, right eye → H35.3211 (with active CNV), H35.3212 (inactive CNV), or H35.3213 (inactive scar) — stage must be documented
- Occult CNV without AMD label → query provider for AMD staging
- Central serous chorioretinopathy → H35.711 if provider documents CSCR as primary diagnosis
- Choroidal neovascularization, right eye → H44.2A1 if documented as primary finding separate from AMD
Clinical Description
The retinal pigment epithelium (RPE) is a monolayer of pigmented cells that lies between the photoreceptors of the neurosensory retina above and Bruch’s membrane below. It performs critical functions including phagocytosis of shed photoreceptor outer segments, vitamin A metabolism, transport of nutrients and waste between the choroid and retina, and maintenance of the outer blood-retinal barrier. Bruch’s membrane is a pentalaminar extracellular matrix separating the RPE from the choriocapillaris.
Pathophysiology of serous PED: Serous fluid accumulates in the sub-RPE space when the integrity of Bruch’s membrane is compromised — most commonly by age-related thickening and calcification — allowing fluid from the choriocapillaris to seep beneath the RPE. In wet AMD, choroidal neovascular membranes (CNV) leak fluid actively beneath the RPE, creating a dome-shaped or irregular elevation. In CSCR, focal RPE pump failure or choroidal hyperpermeability causes serous fluid accumulation beneath both the neurosensory retina and, secondarily, beneath the RPE itself.
OCT characteristics of serous PED (right eye):
- Dome-shaped or irregular elevation of the RPE band
- Optically clear (dark/hyporeflective) space between the RPE and Bruch’s membrane
- Bruch’s membrane visible as a separate hyperreflective line below the elevated RPE in some cases
- Overlying neurosensory retina may be attached or secondarily detached
- No high internal reflectivity within the sub-RPE space (distinguishes from hemorrhagic PED)
Fluorescein angiography (FA) characteristics:
- Early hyperfluorescence with smooth, well-demarcated margins
- Progressive pooling of dye within the PED over the angiographic sequence
- “Inkblot” or “smokestack” pattern may indicate associated CSC
- Hot spot or lacy pattern of active CNV may be identified at the margin of the PED
OCT-Angiography (OCT-A):
- Identifies flow signal within the sub-RPE space indicative of type 1 (sub-RPE) CNV even in the absence of classic FA findings
- Critical for distinguishing drusenoid PED (no flow) from neovascular PED (flow present)
Common etiologies and clinical associations:
- Exudative (wet) AMD with type 1 (occult) CNV — most common cause of serous PED in patients over 60; sub-RPE neovascular network leaks serous fluid without breaking through the RPE initially
- Exudative AMD with type 2 (classic) CNV — PED may coexist with subretinal neovascular membrane
- Central serous chorioretinopathy (CSCR) — more common in middle-aged men; choroidal hyperpermeability drives focal RPE detachments; more common in context of steroid use, stress, type A personality
- Drusenoid PED — large confluent soft drusen creating a dome-shaped elevation; associated with dry AMD and risk of conversion to wet AMD or geographic atrophy
- Polypoidal choroidal vasculopathy (PCV) — variant of neovascular AMD with polypoidal dilations of the inner choroidal vasculature; serous and hemorrhagic PED common; more frequent in Asian and African American populations
- Inflammatory / uveitic — posterior uveitis can drive serous RPE detachments through choroidal inflammation
Coding Guidelines
Official Guideline Reference
ICD-10-CM Official Guidelines FY2025, Section I.C.7 — Diseases of the Eye and Adnexa
- Assign H35.721 when the provider documents serous detachment of the RPE in the right eye in the assessment. Imaging report terminology alone (e.g., “PED noted on OCT”) is insufficient — provider must document the diagnosis in the assessment or plan.
- When serous PED is secondary to wet AMD, code both H35.721 and the appropriate AMD code (H35.3211-H35.3213) — they represent distinct reportable conditions, each with independent HCC weight under CMS-HCC v28.
- Do not assign H35.721 and H35.731 for the same eye without provider documentation confirming both serous and hemorrhagic components as distinct findings (e.g., mixed PED confirmed on OCT and FA with provider documentation of both).
Sequencing Tips
- Outpatient — First-listed diagnosis: H35.721 when serous PED is the primary reason for the encounter; if AMD is the primary diagnosis driving the visit and PED is a secondary finding, sequence the AMD code first
- AMD + PED sequencing: When both exudative AMD (H35.3211) and H35.721 are present, sequence the AMD as first-listed at a visit focused on AMD management (e.g., anti-VEGF injection); H35.721 is additional. At a visit specifically for PED evaluation, H35.721 may be first-listed with AMD as additional.
- Anti-VEGF injection visit: First-listed diagnosis is typically the AMD or the PED — whichever the provider documents as the primary reason for the injection; 67028 is the procedure
- Outpatient — subsequent visits: Re-evaluate whether PED is still present and active — do not carry H35.721 forward if OCT shows resolution; resolved PED should be documented as resolved and dropped from the active problem list
- POA (inpatient): Almost always Y — serous PED is a chronic or subacute condition present before admission in the vast majority of cases
HCC Mapping
HCC Risk Adjustment
HCC Relevant: Yes HCC Model: CMS-HCC v28 HCC Category: Category 124 — Exudative Macular Degeneration and Other Retinal Disorders HCC Coefficient: 0.191 Risk Adjustment Impact: Moderate
A coefficient of 0.191 adds approximately 1,000 of base rate to the annual risk score per Medicare Advantage beneficiary. When H35.721 is coded alongside exudative AMD (H35.3211), both map to HCC 124 — however, HCC 124 is counted once per beneficiary per model year regardless of how many codes map to it. The value is in ensuring at least one HCC 124 code is captured annually.
HCC Capture Tips
- H35.721 independently maps to HCC 124 — it can anchor HCC 124 capture even if the AMD code is missed or insufficiently specific; however, coding both is always preferred for clinical accuracy
- Annual recapture is essential — HCC 124 requires documentation and coding at every data collection year for continuous RAF credit; serous PED is a chronic condition requiring active recapture at every MA encounter where it is assessed
- Do not let PED fall off the problem list after it responds to anti-VEGF treatment — if the condition is still being monitored (even if OCT shows reduction), it remains an active diagnosis reportable at each encounter
- When PED converts to hemorrhagic PED (H35.731), update the code accordingly — both map to HCC 124 but the conversion has clinical significance for treatment planning and documentation
- AMD staging specificity: Ensuring H35.3211 (active CNV) is coded with H35.721 rather than a less specific AMD code (e.g., H35.30) protects HCC capture and provides the most complete clinical picture for audit defense
MS-DRG Mapping
DRG Assignment
MS-DRG Description MDC GMLOS 124 Other Disorders of the Eye with MCC MDC 2 4.6 125 Other Disorders of the Eye with CC or without CC/MCC MDC 2 3.1
CC/MCC Status
- CC status: No — H35.721 does not function as a CC or MCC
- MCC status: No
- HAC designation: No
- POA exempt: No
- Inpatient note: Inpatient admission for serous PED alone is rare. H35.721 most commonly appears as a secondary diagnosis in the inpatient setting. Vitrectomy or intravitreal procedures for AMD-related PED in the inpatient setting are uncommon but possible; DRG assignment is driven by the principal diagnosis and any CC/MCC secondary codes.
CPT Crosswalk
| CPT | Description |
|---|---|
| 67028 | Intravitreal injection of pharmacologic agent (e.g., anti-VEGF — bevacizumab, ranibizumab, aflibercept, faricimab) |
| 67027 | Implantation of intravitreal sustained-release drug delivery system (e.g., fluocinolone — for inflammatory etiology) |
| 67036 | Vitrectomy, mechanical, pars plana approach |
| 67039 | Vitrectomy, pars plana; with focal endolaser photocoagulation |
| 67040 | Vitrectomy, pars plana; with endolaser panretinal photocoagulation |
| 92134 | OCT posterior segment, scanning computerized ophthalmic diagnostic imaging, with interpretation and report |
| 92240 | Indocyanine-green angiography with interpretation and report |
| 92250 | Fundus photography with interpretation and report |
| 92225 | Ophthalmoscopy, extended, with retinal drawing, initial |
| 92226 | Ophthalmoscopy, extended, with retinal drawing, subsequent |
Anti-VEGF Billing for Serous PED
- 67028 is the primary procedure CPT for intravitreal anti-VEGF injection treating serous PED secondary to wet AMD
- The drug itself is billed via HCPCS J-code separately from the injection CPT:
- J0178 — Aflibercept (Eylea®), per 1 mg
- J0179 — Brolucizumab (Beovu®), per 1 mg
- J0180 — Faricimab-svoa (Vabysmo®), per 1 mg
- J2778 — Ranibizumab (Lucentis®), per 0.1 mg
- J9035 — Bevacizumab (Avastin®) — off-label; verify payer coverage
- Modifier -RT required on 67028 for right eye
- If bilateral injections are given same session: two separate lines with -RT and -LT; verify bilateral injection payer policy (50% reduction second eye under Medicare bilateral surgery indicator may apply)
ICD-10-PCS Crosswalk
PCS Applicability
ICD-10-PCS applies in the inpatient setting only. Procedures related to serous PED in the inpatient setting may include intravitreal injection or vitrectomy.
| PCS Code | Root Operation | Body Part | Approach | Device | Qualifier |
|---|---|---|---|---|---|
| 08H63KZ | Insertion | Vitreous, Right | Percutaneous | Synthetic Substitute | No Qualifier |
| 3E023GC | Introduction | Eye, right | Percutaneous | Other Therapeutic Substance | Other Substance (anti-VEGF) |
| 08B33ZZ | Excision | Vitreous, Right | Percutaneous | No Device | No Qualifier |
Character breakdown — intravitreal injection, right eye (3E023GC):
- Section: 3 — Administration
- Body System: E — Physiological Systems and Anatomical Regions
- Root Operation: 0 — Introduction
- Body Part / Region: 02 — Eye
- Approach: 3 — Percutaneous
- Substance: G — Other Therapeutic Substance
- Qualifier: C — Other Substance
ICD-10-CM Crosswalk
| Code | Description | Relationship |
|---|---|---|
| H35.722 | Serous detachment of RPE, left eye | Contralateral equivalent |
| H35.723 | Serous detachment of RPE, bilateral | Bilateral equivalent |
| H35.729 | Serous detachment of RPE, unspecified eye | Less specific — avoid if laterality documented |
| H35.731 | Hemorrhagic detachment of RPE, right eye | Hemorrhagic variant — distinct condition, same subcategory |
| H35.711 | Central serous chorioretinopathy, right eye | Related etiology — CSCR-associated PED; Excludes2 |
| H35.3211 | Exudative AMD, right eye, with active CNV | Most common etiology — code separately; HCC 124 |
| H35.3212 | Exudative AMD, right eye, with inactive CNV | AMD with resolved CNV — may still have residual PED |
| H35.3213 | Exudative AMD, right eye, with inactive scar | Advanced AMD — PED may persist alongside fibrosis |
| H35.3111 | Nonexudative AMD, right eye, early dry stage | Dry AMD — drusenoid PED risk; code separately |
| H35.341 | Macular cyst, hole, or pseudohole, right eye | May coexist in advanced AMD — code separately |
| H35.81 | Retinal edema | May coexist — separately reportable |
| H44.2A1 | Degenerative myopia with choroidal neovascularization, right eye | Alternate etiology for PED in myopic patients |
| H33.001 | Unspecified retinal detachment, right eye | More severe; Excludes1 — not concurrent |
| H30.101 | Unspecified focal chorioretinal inflammation, right eye | Inflammatory etiology for PED |
Coding Examples
Example 1 — Serous PED Right Eye Secondary to Wet AMD, Anti-VEGF Injection Visit, Outpatient
Scenario: A 79-year-old Medicare Advantage patient with known wet AMD presents for scheduled anti-VEGF injection, right eye. OCT shows persistent serous PED right eye with central subfield thickness of 380 microns. Active CNV confirmed on prior OCT-A. Provider documents exudative AMD with active CNV and serous PED, right eye, in the assessment. Aflibercept 2 mg intravitreal injection administered, right eye. First-listed Dx: H35.3211 — Exudative AMD, right eye, with active choroidal neovascularization (primary AMD diagnosis driving the injection) Additional Dx: H35.721 — Serous detachment of RPE, right eye (secondary finding, separately reportable) CPT: 67028-RT — Intravitreal injection, right eye HCPCS: J0178 x 2 units — Aflibercept 2 mg (verify units per payer) Notes: Both H35.3211 and H35.721 map to HCC 124 — coding both maximizes clinical completeness. J0178 unit count must match the documented dose and payer’s billing unit definition. Modifier -RT required on 67028.
Example 2 — Serous PED Right Eye, OCT Monitoring, No Injection This Visit
Scenario: A 74-year-old patient with wet AMD and serous PED right eye presents for OCT monitoring between injection cycles. OCT shows stable serous PED, reduced from prior visit. Provider documents wet AMD with serous PED, right eye, stable — monitoring continued. No injection today. Extended ophthalmoscopy and OCT performed. First-listed Dx: H35.3212 — Exudative AMD, right eye, with inactive choroidal neovascularization (CNV has become inactive per prior treatment — confirm with provider) Additional Dx: H35.721 — Serous detachment of RPE, right eye (still present, being monitored) CPT: 92226-RT — Extended ophthalmoscopy, subsequent; 92134 — OCT posterior segment with interpretation Notes: Even when no injection is given, H35.721 remains reportable as long as PED is present and documented in the assessment. Do not drop the code because treatment was not rendered at this visit. AMD stage should reflect current clinical status — confirm whether CNV is active or inactive with provider.
Example 3 — New Diagnosis Serous PED Right Eye, Rule-Out Wet AMD vs. CSCR, Outpatient
Scenario: A 55-year-old male presents with sudden blurred vision and a gray spot in the right eye. OCT demonstrates serous PED and overlying subretinal fluid, right eye. FA shows pooling without classic CNV pattern. Physician documents serous detachment of RPE, right eye — differential includes CSCR vs. early wet AMD. Indocyanine-green angiography (ICG) ordered. No treatment today. Initial extended ophthalmoscopy and fundus photography performed. First-listed Dx: H35.721 — Serous detachment of RPE, right eye (confirmed finding; etiology under investigation) CPT: 92225-RT — Extended ophthalmoscopy, initial; 92250 — Fundus photography; 92240 — ICG angiography with interpretation Notes: When etiology is under investigation, code the confirmed finding (H35.721) — do not code a suspected diagnosis (wet AMD or CSCR) until confirmed. At the follow-up visit after ICG and clinical evaluation, update to include the confirmed etiology code (H35.3211 for wet AMD or H35.711 for CSCR) once documented by the provider.
Coding Pitfalls & Tips
Common Errors
- Using H35.729 (unspecified eye) when the right eye is clearly documented — always assign H35.721 with confirmed laterality
- Coding H35.721 without the underlying AMD code when exudative AMD is documented — both are independently reportable and both contribute to HCC 124 capture; missing the AMD code leaves clinical context incomplete
- Confusing serous PED (H35.721) with hemorrhagic PED (H35.731) — the distinction requires OCT and FA/ICG interpretation; the provider must specify serous vs. hemorrhagic in the assessment. Do not assign based on imaging report language alone.
- Confusing H35.721 with central serous chorioretinopathy (H35.711) — CSCR primarily involves subretinal fluid beneath the neurosensory retina with secondary RPE changes; serous PED involves primary sub-RPE fluid accumulation. These may coexist but are distinct; provider documentation drives code selection.
- Carrying H35.721 forward after OCT-confirmed PED resolution — re-evaluate at each visit; resolved PED should be retired from the active diagnosis list
- Failing to update AMD stage (active CNV → inactive CNV → inactive scar) as treatment response changes — the AMD staging code must reflect current clinical status, not the status at initial diagnosis
- Missing the J-code for the anti-VEGF drug — the 67028 CPT covers the injection procedure only; the drug is billed separately via the appropriate HCPCS J-code
Pro Tips
- OCT-A is increasingly used to identify type 1 (sub-RPE) CNV — if OCT-A shows flow under the RPE and the provider documents active CNV, code H35.3211 even without classic FA findings. Do not default to dry AMD coding when OCT-A-confirmed CNV is documented.
- Drusenoid PED — a dome-shaped RPE elevation caused by large confluent soft drusen without true sub-RPE fluid — technically maps to H35.721 if the provider documents it as a PED; however, some providers prefer to document this only as drusen (H35.361). Follow provider documentation language.
- When a patient transitions from serous PED (H35.721) to hemorrhagic PED (H35.731) — a known complication of untreated or undertreated wet AMD — update the code immediately and document the conversion event clearly in the coding record
- For bilateral PED (both eyes affected), use H35.723 — do not code H35.721 + H35.722 simultaneously
- ICG angiography (92240) is critical for diagnosing polypoidal choroidal vasculopathy (PCV) — if PCV is confirmed, this affects treatment planning (PDT + anti-VEGF) and should be documented in the provider assessment for clinical completeness, even if no separate ICD-10 code for PCV exists distinct from neovascular AMD
CDI Query Opportunities
CDI Flags
- AMD staging: Is the AMD documented as exudative (wet) or nonexudative (dry)? Is CNV active or inactive? What is the current stage? — AMD staging drives the specific H35.32x code that pairs with H35.721 and determines HCC 124 capture strength
- Serous vs. hemorrhagic PED: Does OCT or FA confirm purely serous fluid, hemorrhagic fluid, or a mixed PED? Query provider to specify type in the assessment — code selection between H35.721 and H35.731 depends on provider documentation, not imaging report interpretation alone
- Etiology clarification: Is the serous PED secondary to wet AMD, CSCR, PCV, or another condition? Query if only “serous PED” is documented without an associated etiology — the underlying condition carries independent coding and HCC weight
- CNV activity status: After anti-VEGF treatment, is the CNV still active or has it become inactive? Provider must document active vs. inactive CNV status to support correct AMD staging code (H35.3211 vs. H35.3212) at each follow-up visit
- Bilateral involvement: Is there any evidence of serous PED in the left eye on OCT? If bilateral, query for bilateral documentation → H35.723
- Subretinal fluid vs. sub-RPE fluid: Does the provider distinguish subretinal fluid (above the RPE, beneath the neurosensory retina) from sub-RPE fluid (serous PED)? Both may be present simultaneously in wet AMD; documentation of both supports H35.721 + H35.3211 coding
- Annual recapture (HCC): Is this a Medicare Advantage patient? Confirm H35.721 and the associated AMD code are captured at every encounter — not just at initial diagnosis or injection visits — for continuous HCC 124 RAF credit
Related Codes
- Laterality family: H35.722, H35.723, H35.729
- Hemorrhagic variant: H35.731, H35.732, H35.733
- CSCR family: H35.711, H35.712, H35.713
- Primary etiology — wet AMD: H35.3211, H35.3212, H35.3213
- Primary etiology — dry AMD: H35.3111, H35.3112, H35.3113, H35.3114
- Associated macular findings: H35.341, H35.351, H35.81
- Choroidal neovascularization: H44.2A1
- CPT crosswalk: 67028, 67027, 92134, 92240, 92250, 92225, 92226
- PCS crosswalk: 08H63KZ, 3E023GC, 08B33ZZ
Sources
ICD-10-CM Official Guidelines for Coding and Reporting FY2025. CMS/NCHS. ICD-10-CM Tabular List of Diseases and Injuries FY2025. CMS. CMS MS-DRG Definitions Manual v42. Centers for Medicare & Medicaid Services. CMS-HCC Risk Adjustment Model v28 Coefficients and Category Mappings. CMS, 2024. AHA Coding Clinic for ICD-10-CM/PCS. American Hospital Association. AAO Coding Coach — Ophthalmology CPT and ICD-10 Reference 2025. American Academy of Ophthalmology. Freund KB, et al. Pigment epithelial detachments in age-related macular degeneration. Retina. 2013. Spaide RF, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data. Ophthalmology. 2020. CMS NCCI Policy Manual FY2025, Chapter 9 — Eye and Ocular Adnexa. applies in the inpatient setting only. Procedures related to serous PED in the inpatient setting may include intravitreal injection or vitrectomy.
| PCS Code | Root Operation | Body Part | Approach | Device | Qualifier |
|---|---|---|---|---|---|
| 08H63KZ | Insertion | Vitreous, Right | Percutaneous | Synthetic Substitute | No Qualifier |
| 3E023GC | Introduction | Eye, right | Percutaneous | Other Therapeutic Substance | Other Substance (anti-VEGF) |
| 08B33ZZ | Excision | Vitreous, Right | Percutaneous | No Device | No Qualifier |
Character breakdown — intravitreal injection, right eye (3E023GC):
- Section: 3 — Administration
- Body System: E — Physiological Systems and Anatomical Regions
- Root Operation: 0 — Introduction
- Body Part / Region: 02 — Eye
- Approach: 3 — Percutaneous
- Substance: G — Other Therapeutic Substance
- Qualifier: C — Other Substance
ICD-10-CM Crosswalk
| Code | Description | Relationship |
|---|---|---|
| H35.722 | Serous detachment of RPE, left eye | Contralateral equivalent |
| H35.723 | Serous detachment of RPE, bilateral | Bilateral equivalent |
| H35.729 | Serous detachment of RPE, unspecified eye | Less specific — avoid if laterality documented |
| H35.731 | Hemorrhagic detachment of RPE, right eye | Hemorrhagic variant — distinct condition, same subcategory |
| H35.711 | Central serous chorioretinopathy, right eye | Related etiology — CSCR-associated PED; Excludes2 |
| H35.3211 | Exudative AMD, right eye, with active CNV | Most common etiology — code separately; HCC 124 |
| H35.3212 | Exudative AMD, right eye, with inactive CNV | AMD with resolved CNV — may still have residual PED |
| H35.3213 | Exudative AMD, right eye, with inactive scar | Advanced AMD — PED may persist alongside fibrosis |
| H35.3111 | Nonexudative AMD, right eye, early dry stage | Dry AMD — drusenoid PED risk; code separately |
| H35.341 | Macular cyst, hole, or pseudohole, right eye | May coexist in advanced AMD — code separately |
| H35.81 | Retinal edema | May coexist — separately reportable |
| H44.2A1 | Degenerative myopia with choroidal neovascularization, right eye | Alternate etiology for PED in myopic patients |
| H33.001 | Unspecified retinal detachment, right eye | More severe; Excludes1 — not concurrent |
| H30.101 | Unspecified focal chorioretinal inflammation, right eye | Inflammatory etiology for PED |
Coding Examples
Example 1 — Serous PED Right Eye Secondary to Wet AMD, Anti-VEGF Injection Visit, Outpatient
Scenario: A 79-year-old Medicare Advantage patient with known wet AMD presents for scheduled anti-VEGF injection, right eye. OCT shows persistent serous PED right eye with central subfield thickness of 380 microns. Active CNV confirmed on prior OCT-A. Provider documents exudative AMD with active CNV and serous PED, right eye, in the assessment. Aflibercept 2 mg intravitreal injection administered, right eye. First-listed Dx: H35.3211 — Exudative AMD, right eye, with active choroidal neovascularization (primary AMD diagnosis driving the injection) Additional Dx: H35.721 — Serous detachment of RPE, right eye (secondary finding, separately reportable) CPT: 67028-RT — Intravitreal injection, right eye HCPCS: J0178 x 2 units — Aflibercept 2 mg (verify units per payer) Notes: Both H35.3211 and H35.721 map to HCC 124 — coding both maximizes clinical completeness. J0178 unit count must match the documented dose and payer’s billing unit definition. Modifier-RT required on 67028.
Example 2 — Serous PED Right Eye, OCT Monitoring, No Injection This Visit
Scenario: A 74-year-old patient with wet AMD and serous PED right eye presents for OCT monitoring between injection cycles. OCT shows stable serous PED, reduced from prior visit. Provider documents wet AMD with serous PED, right eye, stable — monitoring continued. No injection today. Extended ophthalmoscopy and OCT performed. First-listed Dx: H35.3212 — Exudative AMD, right eye, with inactive choroidal neovascularization (CNV has become inactive per prior treatment — confirm with provider) Additional Dx: H35.721 — Serous detachment of RPE, right eye (still present, being monitored) CPT: 92226-RT — Extended ophthalmoscopy, subsequent; 92134 — OCT posterior segment with interpretation Notes: Even when no injection is given, H35.721 remains reportable as long as PED is present and documented in the assessment. Do not drop the code because treatment was not rendered at this visit. AMD stage should reflect current clinical status — confirm whether CNV is active or inactive with provider.
Example 3 — New Diagnosis Serous PED Right Eye, Rule-Out Wet AMD vs. CSCR, Outpatient
Scenario: A 55-year-old male presents with sudden blurred vision and a gray spot in the right eye. OCT demonstrates serous PED and overlying subretinal fluid, right eye. FA shows pooling without classic CNV pattern. Physician documents serous detachment of RPE, right eye — differential includes CSCR vs. early wet AMD. Indocyanine-green angiography (ICG) ordered. No treatment today. Initial extended ophthalmoscopy and fundus photography performed. First-listed Dx: H35.721 — Serous detachment of RPE, right eye (confirmed finding; etiology under investigation) CPT: 92225-RT — Extended ophthalmoscopy, initial; 92250 — Fundus photography; 92240 — ICG angiography with interpretation Notes: When etiology is under investigation, code the confirmed finding (H35.721) — do not code a suspected diagnosis (wet AMD or CSCR) until confirmed. At the follow-up visit after ICG and clinical evaluation, update to include the confirmed etiology code (H35.3211 for wet AMD or H35.711 for CSCR) once documented by the provider.
Coding Pitfalls & Tips
Common Errors
- Using H35.729 (unspecified eye) when the right eye is clearly documented — always assign H35.721 with confirmed laterality
- Coding H35.721 without the underlying AMD code when exudative AMD is documented — both are independently reportable and both contribute to HCC 124 capture; missing the AMD code leaves clinical context incomplete
- Confusing serous PED (H35.721) with hemorrhagic PED (H35.731) — the distinction requires OCT and FA/ICG interpretation; the provider must specify serous vs. hemorrhagic in the assessment. Do not assign based on imaging report language alone.
- Confusing H35.721 with central serous chorioretinopathy (H35.711) — CSCR primarily involves subretinal fluid beneath the neurosensory retina with secondary RPE changes; serous PED involves primary sub-RPE fluid accumulation. These may coexist but are distinct; provider documentation drives code selection.
- Carrying H35.721 forward after OCT-confirmed PED resolution — re-evaluate at each visit; resolved PED should be retired from the active diagnosis list
- Failing to update AMD stage (active CNV → inactive CNV → inactive scar) as treatment response changes — the AMD staging code must reflect current clinical status, not the status at initial diagnosis
- Missing the J-code for the anti-VEGF drug — the 67028 CPT covers the injection procedure only; the drug is billed separately via the appropriate HCPCS J-code
Pro Tips
- OCT-A is increasingly used to identify type 1 (sub-RPE) CNV — if OCT-A shows flow under the RPE and the provider documents active CNV, code H35.3211 even without classic FA findings. Do not default to dry AMD coding when OCT-A-confirmed CNV is documented.
- Drusenoid PED — a dome-shaped RPE elevation caused by large confluent soft drusen without true sub-RPE fluid — technically maps to H35.721 if the provider documents it as a PED; however, some providers prefer to document this only as drusen (H35.361). Follow provider documentation language.
- When a patient transitions from serous PED (H35.721) to hemorrhagic PED (H35.731) — a known complication of untreated or undertreated wet AMD — update the code immediately and document the conversion event clearly in the coding record
- For bilateral PED (both eyes affected), use H35.723 — do not code H35.721 + H35.722 simultaneously
- ICG angiography (92240) is critical for diagnosing polypoidal choroidal vasculopathy (PCV) — if PCV is confirmed, this affects treatment planning (PDT + anti-VEGF) and should be documented in the provider assessment for clinical completeness, even if no separate ICD-10 code for PCV exists distinct from neovascular AMD
CDI Query Opportunities
CDI Flags
- AMD staging: Is the AMD documented as exudative (wet) or nonexudative (dry)? Is CNV active or inactive? What is the current stage? — AMD staging drives the specific H35.32x code that pairs with H35.721 and determines HCC 124 capture strength
- Serous vs. hemorrhagic PED: Does OCT or FA confirm purely serous fluid, hemorrhagic fluid, or a mixed PED? Query provider to specify type in the assessment — code selection between H35.721 and H35.731 depends on provider documentation, not imaging report interpretation alone
- Etiology clarification: Is the serous PED secondary to wet AMD, CSCR, PCV, or another condition? Query if only “serous PED” is documented without an associated etiology — the underlying condition carries independent coding and HCC weight
- CNV activity status: After anti-VEGF treatment, is the CNV still active or has it become inactive? Provider must document active vs. inactive CNV status to support correct AMD staging code (H35.3211 vs. H35.3212) at each follow-up visit
- Bilateral involvement: Is there any evidence of serous PED in the left eye on OCT? If bilateral, query for bilateral documentation → H35.723
- Subretinal fluid vs. sub-RPE fluid: Does the provider distinguish subretinal fluid (above the RPE, beneath the neurosensory retina) from sub-RPE fluid (serous PED)? Both may be present simultaneously in wet AMD; documentation of both supports H35.721 + H35.3211 coding
- Annual recapture (HCC): Is this a Medicare Advantage patient? Confirm H35.721 and the associated AMD code are captured at every encounter — not just at initial diagnosis or injection visits — for continuous HCC 124 RAF credit
Related Codes
- Laterality family: H35.722, H35.723, H35.729
- Hemorrhagic variant: H35.731, H35.732, H35.733
- CSCR family: H35.711, H35.712, H35.713
- Primary etiology — wet AMD: H35.3211, H35.3212, H35.3213
- Primary etiology — dry AMD: H35.3111, H35.3112, H35.3113, H35.3114
- Associated macular findings: H35.341, H35.351, H35.81
- Choroidal neovascularization: H44.2A1
- CPT crosswalk: 67028, 67027, 92134, 92240, 92250, 92225, 92226
- PCS crosswalk: 08H63KZ, 3E023GC, 08B33ZZ
Sources
ICD-10-CM Official Guidelines for Coding and Reporting FY2025. CMS/NCHS. ICD-10-CM Tabular List of Diseases and Injuries FY2025. CMS. CMS MS-DRG Definitions Manual v42. Centers for Medicare & Medicaid Services. CMS-HCC Risk Adjustment Model v28 Coefficients and Category Mappings. CMS, 2024. AHA Coding Clinic for ICD-10-CM/PCS. American Hospital Association. AAO Coding Coach — Ophthalmology CPT and ICD-10 Reference 2025. American Academy of Ophthalmology. Freund KB, et al. Pigment epithelial detachments in age-related macular degeneration. Retina. 2013. Spaide RF, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data. Ophthalmology. 2020. CMS NCCI Policy Manual FY2025, Chapter 9 — Eye and Ocular Adnexa.